US 10,888,546 B2
Pharmaceutical composition
Stuart Corr, Cheshire (GB); and Timothy James Noakes, Flintshire (GB)
Assigned to MEXICHEM FLUOR S.A. DE C.V., San Luis Potosi (MX)
Appl. No. 16/334,158
Filed by MEXICHEM FLUOR S.A. DE C.V., San Luis Potosi (MX)
PCT Filed Sep. 18, 2017, PCT No. PCT/GB2017/052761
§ 371(c)(1), (2) Date Mar. 18, 2019,
PCT Pub. No. WO2018/051130, PCT Pub. Date Mar. 22, 2018.
Claims priority of application No. 1615917.0 (GB), filed on Sep. 19, 2016; and application No. 1620519.7 (GB), filed on Dec. 2, 2016.
Prior Publication US 2019/0255018 A1, Aug. 22, 2019
Int. Cl. A61K 31/40 (2006.01); A61K 47/58 (2017.01); A61P 11/00 (2006.01); A61K 9/00 (2006.01); A61K 31/4704 (2006.01); A61K 31/573 (2006.01); A61K 47/10 (2017.01); A61K 47/24 (2006.01); A61K 45/06 (2006.01); A61K 31/56 (2006.01); A61K 47/12 (2006.01); A61K 47/32 (2006.01)
CPC A61K 31/40 (2013.01) [A61K 9/008 (2013.01); A61K 31/4704 (2013.01); A61K 31/56 (2013.01); A61K 31/573 (2013.01); A61K 45/06 (2013.01); A61K 47/10 (2013.01); A61K 47/12 (2013.01); A61K 47/24 (2013.01); A61K 47/32 (2013.01); A61K 47/58 (2017.08); A61P 11/00 (2018.01)] 28 Claims
 
1. A pharmaceutical composition for a metered dose inhaler comprising:
a drug component consisting of glycopyrronium bromide, fluticasone propionate and optionally at least one long acting beta-2-agonist selected from the group consisting of indacaterol and indacaterol maleate; and
(ii) a propellant component comprising 1,1-difluoroethane (HFA-152a), wherein the composition contains greater than 0.5 ppm and less than 500 ppm of water based on the total weight of the pharmaceutical composition.